Biopharma AI

Can Hippocratic AI’s Acquisition of Grove AI Trigger the Shift from Fragmented Pilots to a Unified Agentic AI Platform in Biopharma?

Executive SummaryAt the 2026 JPM Healthcare Conference in San Francisco, Hippocratic AI announced the acquisition of Grove AI,…

ByByAnuja Singh Feb 28, 2026

Top 10 Pharma Brands of 2025 — Sales Performance, Company Strategy & Market Outlook

The pharmaceutical market in 2025 was defined by high-value specialty brands delivering breakthrough outcomes in oncology, metabolic disease,…

ByByAnuja Singh Feb 14, 2026

Big Pharma Accelerates Shift to Off-the-Shelf Cell Therapy with Strategic Acquisitions

The global biopharmaceutical industry is entering a new phase in cell therapy innovation, marked by significant investments in…

ByByAnuja Singh Feb 14, 2026

Drugmakers Use AI to Speed Trials and Regulatory Filings

Pharmaceutical companies are increasingly using artificial intelligence to streamline clinical trials and regulatory filings. While AI has not…

ByByAnuja Singh Feb 14, 2026
Image Not Found

VA’s Nationwide Ambient AI Scribe Rollout: Burnout Buster or Documentation Digitized Trap?

The U.S. Department of Veterans Affairs on March 4, 2026, greenlit ambient scribe AI from Knowtex and Abridge…

ByByAnuja Singh Mar 4, 2026

AI in Clinical Trials: Breakthrough Efficiency or Bottlenecked by Biology’s Chaos?

AI is slashing clinical trial timelines and costs where data flows freely—think 35-50% faster enrollment and 30% OpEx…

ByByAnuja Singh Mar 3, 2026
Scroll to Top